DrugPatentWatch Database Preview
COREG CR Drug Profile
see a sample report or, see our see our flat-rate plans
Which patents cover Coreg Cr, and when can generic versions of Coreg Cr launch?
This drug has fifty patent family members in sixteen countries.
The generic ingredient in COREG CR is carvedilol phosphate. There are thirty-six drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the carvedilol phosphate profile page.
Summary for COREG CR
| International Patents: | 50 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 4 |
| Bulk Api Vendors: | 123 |
| Patent Applications: | 4,179 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for COREG CR |
| DailyMed Link: | COREG CR at DailyMed |
Pharmacology for COREG CR
| Drug Class | alpha-Adrenergic Blocker beta-Adrenergic Blocker |
| Mechanism of Action | Adrenergic alpha-Antagonists Adrenergic beta1-Antagonists Adrenergic beta2-Antagonists |
Synonyms for COREG CR
| (+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol |
| (+-)-1-Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol |
| (+/-)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol |
| (2RS)-1-(9H-Carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol phosphate salt (1:1) |
| (2RS)-1-(9H-Carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol phosphate salt (1:1) hemihydrate |
| (2RS)-1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]propan-2-ol phosphate salt (1:1) hemihydrate |
| [3-(9H-carbazol-4-yloxy)-2-hydroxypropyl][2-(2-methoxyphenoxy)ethyl]amine |
| 1-((9H-Carbazol-4-yl)oxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol |
| 1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol |
| 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol |
| 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol |
| 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol |
| 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol; phosphoric acid; hydrate |
| 1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol |
| 1-9H-(Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol phosphate hemihydrate |
| 102641-EP2270011A1 |
| 102641-EP2272841A1 |
| 102641-EP2275420A1 |
| 102641-EP2298764A1 |
| 102641-EP2298765A1 |
| 102641-EP2301936A1 |
| 107741-96-8 |
| 1196658-85-1 |
| 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, (+-)- |
| 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, phosphate (1:1) |
| 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, phosphate (salt), hydrate (2:2:1) |
| 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, phosphate, hydrate (1:1:1) |
| 309C892 |
| 374779-45-0 |
| 610309-89-2 |
| 72956-09-3 |
| 956C093 |
| AB0008431 |
| AB00639903_10 |
| AB00639903_11 |
| AB00639903_12 |
| AB00639903-07 |
| AB00639903-09 |
| AB1004830 |
| AC-1641 |
| AC1L1E0B |
| AK163147 |
| AKOS005554967 |
| AKOS026749869 |
| AN-14749 |
| AN-27765 |
| API0001873 |
| Artist |
| Artist (TN) |
| Atlana Pharma brand of carvedilol |
| AX8120145 |
| BBL029064 |
| BC204100 |
| BCP0726000253 |
| BCP9000493 |
| BDBM25759 |
| BG0129 |
| Bio-0014 |
| BIS(1-(9H-CARBAZOL-4-YLOXY)-3-{[2-(2-METHOXYPHENOXY)ETHYL]AMINO}PROPAN-2-OL) BIS(PHOSPHORIC ACID) HYDRATE |
| BM 14,190 |
| BM 14.190 |
| BM 14190 |
| BM-14-190 |
| BM-14.190 |
| BM-14190 |
| BRD-A10977446-001-04-8 |
| BRD-A10977446-045-01-1 |
| C-21835 |
| C06875 |
| C24H26N2O4 |
| C24H31N2O9P |
| Carloc |
| Carloc (TN) |
| carvedilol |
| Carvedilol (JAN/USAN/INN) |
| Carvedilol (phosphate hemihydrate) |
| Carvedilol [USAN:INN:BAN:JAN] |
| Carvedilol [USAN:USP:INN:BAN:JAN] |
| Carvedilol 1.0 mg/ml in Methanol |
| Carvedilol dihydrogen phosphate hemihydrate |
| Carvedilol for system suitability, European Pharmacopoeia (EP) Reference Standard |
| carvedilol HCl |
| Carvedilol hydrochloride |
| Carvedilol phosphate |
| Carvedilol phosphate (USAN) |
| Carvedilol phosphate [USAN] |
| Carvedilol phosphate anhydrous |
| Carvedilol phosphate hemihydrate |
| Carvedilol phosphate hydrate (JAN) |
| Carvedilol phosphate monohydrate |
| carvedilol, (+-)-isomer |
| carvedilol, (R)-isomer |
| carvedilol, (S)-isomer |
| Carvedilol, >=98% (HPLC), solid |
| carvedilol, 14C-labeled |
| Carvedilol, European Pharmacopoeia (EP) Reference Standard |
| Carvedilol, pharmaceutical secondary standard; traceable to USP and PhEur |
| Carvedilol, United States Pharmacopeia (USP) Reference Standard |
| Carvedilolum |
| Carvedilolum [Latin] |
| carvediol |
| CC-25436 |
| CCG-100917 |
| CCG-207952 |
| CCG-213312 |
| CHEBI:3441 |
| CHEMBL1201167 |
| CHEMBL723 |
| Coreg |
| Coreg (TN) |
| Coreg CR (TN) |
| Coropres |
| Coropress |
| CPD000449280 |
| CS-1194 |
| CTK3J2232 |
| D00255 |
| D03415 |
| D0W9LX |
| DB01136 |
| Dibloc |
| Dilatrend |
| Dilatrend (TN) |
| DQ 2466 |
| DQ-2466 |
| DTXSID8022747 |
| EG-P042 |
| Eucardic |
| Eucardic (TN) |
| FT-0603059 |
| FT-0652640 |
| GlaxoSmithKline brand of carvedilol |
| GTPL551 |
| HMS2051N03 |
| HMS2089B09 |
| HMS2093E12 |
| HMS3261E15 |
| HMS3269N11 |
| HMS3393N03 |
| HMS3655O14 |
| HSDB 7044 |
| HY-B0006 |
| I06-0064 |
| I06-1477 |
| J10039 |
| JAYBFQXVKDGMFT-UHFFFAOYSA-N |
| KB-75594 |
| KBio2_002145 |
| KBio2_004713 |
| KBio2_007281 |
| KBio3_002323 |
| KBioGR_001252 |
| KBioSS_002145 |
| Kredex |
| KS-00000XRT |
| KS-1037 |
| KSC492E3F |
| L001243 |
| Lakeside brand of carvedilol |
| LHNYXTULDSJZRB-UHFFFAOYSA-N |
| LP00347 |
| LS-121875 |
| LS-186601 |
| MCULE-7944987271 |
| MFCD00864692 |
| MLS000758299 |
| MLS000759508 |
| MLS001424092 |
| MLS006011886 |
| MolPort-003-666-814 |
| NC00167 |
| NCGC00167832-01 |
| NCGC00167832-02 |
| NCGC00167832-03 |
| NCGC00167832-04 |
| NCGC00261032-01 |
| NSC-751177 |
| NSC-758694 |
| NSC751177 |
| NSC758694 |
| OGHNVEJMJSYVRP-UHFFFAOYSA-N |
| Pharmakon1600-01504257 |
| PL008198 |
| PL039781 |
| PL061817 |
| PL068260 |
| PubChem18218 |
| Q-200801 |
| Querto |
| Roche brand of carvedilol |
| RTR-037608 |
| s1831 |
| SAM001246736 |
| SAM001247021 |
| SBI-0206771.P001 |
| SC-13445 |
| SCHEMBL10082334 |
| SCHEMBL13287211 |
| SCHEMBL194220 |
| SCHEMBL22293 |
| SCHEMBL599530 |
| SK&F-105517 |
| SK&F-105517-D |
| SKF 105517 |
| SKF 105517D |
| SMR000449280 |
| SPBio_001885 |
| Spectrum_001665 |
| Spectrum2_001673 |
| Spectrum3_001182 |
| Spectrum4_000636 |
| Spectrum5_001436 |
| SR-01000759289 |
| SR-01000759289-9 |
| ST24036957 |
| STK621453 |
| TL8005080 |
| Tox21_500347 |
| TR-037608 |
| W-5131 |
| W0023 |
| Z2786051695 |
US Patents and Regulatory Information for COREG CR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-001 | Oct 20, 2006 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-004 | Oct 20, 2006 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-002 | Oct 20, 2006 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-004 | Oct 20, 2006 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Expired US Patents for COREG CR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-001 | Oct 20, 2006 | ➤ Sign Up | ➤ Sign Up |
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-003 | Oct 20, 2006 | ➤ Sign Up | ➤ Sign Up |
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-003 | Oct 20, 2006 | ➤ Sign Up | ➤ Sign Up |
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-003 | Oct 20, 2006 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for COREG CR
| Drugname | Dosage | Strength | RLD | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsules | 10 mg and 20 mg | ➤ Subscribe | 2008-03-18 |
| ➤ Subscribe | Extended-release Capsules | 40 mg | ➤ Subscribe | 2007-12-21 |
| ➤ Subscribe | Extended-release Capsules | 80 mg | ➤ Subscribe | 2007-11-19 |
Non-Orange Book US Patents for COREG CR
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 7,902,378 | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment | ➤ Sign Up |
| 7,626,041 | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment | ➤ Sign Up |
| 7,893,100 | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment | ➤ Sign Up |
| 7,759,384 | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
see a sample report or, see our see our flat-rate plans
